Marco Montillo

12.0k total citations · 3 hit papers
156 papers, 4.7k citations indexed

About

Marco Montillo is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Marco Montillo has authored 156 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 132 papers in Genetics, 86 papers in Pathology and Forensic Medicine and 55 papers in Immunology. Recurrent topics in Marco Montillo's work include Chronic Lymphocytic Leukemia Research (126 papers), Lymphoma Diagnosis and Treatment (86 papers) and Immunodeficiency and Autoimmune Disorders (50 papers). Marco Montillo is often cited by papers focused on Chronic Lymphocytic Leukemia Research (126 papers), Lymphoma Diagnosis and Treatment (86 papers) and Immunodeficiency and Autoimmune Disorders (50 papers). Marco Montillo collaborates with scholars based in Italy, United States and United Kingdom. Marco Montillo's co-authors include Enrica Morra, Alessandra Tedeschi, Tadeusz Robak, Peter Hillmen, Thomas J. Kipps, Roberto Cairoli, Ulrich Jaeger, Annamaria Nosari, Javier Loscertales and Javier de la Serna and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Marco Montillo

151 papers receiving 4.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

2018 595 citations John F. Seymour, Thomas J. Kipps et al. profile →
Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma

2019 307 citations Susan O’Brien, Constantine S. Tam et al. American Journal of Hematology profile →
Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting

2019 286 citations Marco Montillo et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marco Montillo Italy	35	3.0k	2.4k	1.3k	1.3k	797	156	4.7k
Xavier Troussard France	35	2.0k 0.7×	1.9k 0.8×	991 0.7×	1.1k 0.9×	1.3k 1.6×	244	4.6k
Lubomir Sokol United States	37	1.4k 0.5×	2.0k 0.8×	1.4k 1.1×	1.3k 1.1×	1.8k 2.3×	269	5.3k
Alessandro Pulsoni Italy	30	1.2k 0.4×	2.1k 0.9×	524 0.4×	858 0.7×	1.9k 2.4×	143	4.5k
G. Verhoef Belgium	35	1.1k 0.4×	1.4k 0.6×	544 0.4×	1.7k 1.3×	1.5k 1.8×	103	4.4k
Jerzy Hołowiecki Poland	28	1.5k 0.5×	1.1k 0.5×	613 0.5×	1.8k 1.4×	1.4k 1.8×	139	4.8k
Dominique Bordessoule France	39	1.9k 0.6×	2.3k 1.0×	1.1k 0.8×	2.3k 1.8×	2.2k 2.8×	188	6.3k
Silvia Montoto United Kingdom	41	1.3k 0.4×	3.1k 1.3×	785 0.6×	1.4k 1.1×	2.8k 3.5×	165	5.2k
Enrica Morra Italy	46	5.4k 1.8×	2.5k 1.0×	1.3k 1.0×	4.5k 3.5×	1.3k 1.6×	238	8.7k
Renato Fanin Italy	42	1.4k 0.5×	1.3k 0.5×	1.2k 0.9×	3.6k 2.8×	2.0k 2.5×	226	6.6k
Roberto Marasca Italy	35	1.4k 0.5×	1.2k 0.5×	742 0.6×	821 0.6×	1.8k 2.2×	128	4.1k

Countries citing papers authored by Marco Montillo

Since Specialization

Citations

This map shows the geographic impact of Marco Montillo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marco Montillo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marco Montillo more than expected).

Fields of papers citing papers by Marco Montillo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marco Montillo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marco Montillo. The network helps show where Marco Montillo may publish in the future.

Co-authorship network of co-authors of Marco Montillo

This figure shows the co-authorship network connecting the top 25 collaborators of Marco Montillo. A scholar is included among the top collaborators of Marco Montillo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marco Montillo. Marco Montillo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Deodato, Marina, Anna Maria Frustaci, Carlo Gambacorti‐Passerini, et al.. (2024). Advances in the understanding of molecular genetics and therapy of Richter transformation in chronic lymphocytic leukemia. Leukemia & lymphoma. 65(14). 2096–2107. 1 indexed citations

Kater, Arnon P., Rosemary Harrup, Thomas J. Kipps, et al.. (2023). MURANO: Final 7 year follow up and retreatment analysis in venetoclax‐rituximab (VenR)‐treated patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL). Hematological Oncology. 41(S2). 239–242. 8 indexed citations

Frustaci, Anna Maria, Marco Montillo, Davide Rossi, et al.. (2023). S147: EFFICACY AND SAFETY RESULTS OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME. HemaSphere. 7(S3). e6990566–e6990566. 1 indexed citations

Frustaci, Anna Maria, Marco Montillo, Davide Rossi, et al.. (2023). EFFICACY AND SAFETY OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME. Hematological Oncology. 41(S2). 62–63. 2 indexed citations

Frustaci, Anna Maria, et al.. (2023). Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities. Cancers. 15(5). 1504–1504. 31 indexed citations

Davids, Matthew S., Bryone J. Kuss, Peter Hillmen, et al.. (2020). Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study. Clinical Cancer Research. 26(9). 2096–2103. 33 indexed citations

Frustaci, Anna Maria, Chiara Rusconi, Silvio Veronese, et al.. (2015). Bing Neel Syndrome in a Previously Untreated Patient With Waldenström's Macroglobulinemia: Contribution of MYD88 L265P Mutation on Cerebrospinal Fluid. Clinical Lymphoma Myeloma & Leukemia. 16(1). e7–e9. 7 indexed citations

Steurer, Michael, Lydia Scarfò, Marco Montillo, et al.. (2014). INTERIM RESULTS FROM A PHASE IIA STUDY OF THE ANTI-CXCL12 SPIEGELMER OLAPTESED PEGOL (NOX-A12) IN COMBINATION WITH BENDAMUSTINE/RITUXIMAB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA. Haematologica. 99. 59–59. 2 indexed citations

Hillmen, Peter, Tadeusz Robak, Ann Janssens, et al.. (2013). Ofatumumab + Chlorambucil Versus Chlorambucil Alone In Patients With Untreated Chronic Lymphocytic Leukemia (CLL): Results Of The Phase III Study Complement 1 (OMB110911). Blood. 122(21). 528–528. 58 indexed citations

10.

Ricci, Francesca, Alessandra Tedeschi, Chiara Colombo, et al.. (2013). Should a Positive Direct Antiglobulin Test Be Considered a Prognostic Predictor in Chronic Lymphocytic Leukemia?. Clinical Lymphoma Myeloma & Leukemia. 13(4). 441–446. 10 indexed citations

11.

Bulian, Pietro, Davide Rossi, Francesco Forconi, et al.. (2012). IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia. Journal of Translational Medicine. 10(1). 18–18. 21 indexed citations

12.

Mauro, Francesca Romana, Giuseppe Bandini, Giovanni Barosi, et al.. (2011). SIE, SIES, GITMO updated clinical recommendations for the management of chronic lymphocytic leukemia. Leukemia Research. 36(4). 459–466. 6 indexed citations

13.

Herbrecht, Raoul, A.M. Liberati, Javier Loscertales, et al.. (2009). Bendamustine versus chlorambucil in treatment- naive patients with chronic lymphocytic leukemia: Updated results of an international phase III study. Lund University Publications (Lund University). 94. 355–355. 1 indexed citations

14.

Montillo, Marco, Alessandra Tedeschi, Sara Miqueleiz, et al.. (2006). Alemtuzumab As Consolidation After a Response to Fludarabine Is Effective in Purging Residual Disease in Patients With Chronic Lymphocytic Leukemia. Journal of Clinical Oncology. 24(15). 2337–2342. 111 indexed citations

15.

Montillo, Marco, Francesca Ricci, & Alessandra Tedeschi. (2006). Role of fludarabine in hematological malignancies. Expert Review of Anticancer Therapy. 6(9). 1141–1161. 17 indexed citations

16.

Albitar, Maher, Yang O. Huh, Susan O’Brien, et al.. (2002). The clinical and diagnostic relevance of CD23 expression in the chronic lymphoproliferative disease. Cancer. 94(6). 1721–1730. 44 indexed citations

17.

Morra, Enrica, Annamaria Nosari, & Marco Montillo. (1999). Infectious complications in chronic lymphocytic leukaemia. PubMed. 41(4). 145–151. 39 indexed citations

18.

Montillo, Marco, Salvatore Mirto, Maria Concetta Petti, et al.. (1998). Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia. American Journal of Hematology. 58(2). 105–109. 94 indexed citations

19.

Pagano, Livio, Paolo Ricci, Annamaria Nosari, et al.. (1995). Fatal haemoptysis in pulmonary filamentous mycosis: an underevaluated cause of death in patients with acute leukaemia in haematological complete remission. A retrospective study and review of the literature. British Journal of Haematology. 89(3). 500–505. 67 indexed citations

20.

Montillo, Marco, Marina Scarpelli, Giancarlo Discepoli, et al.. (1994). Meningioma-like Cerebral Relapse of Hodgkin's Disease. Leukemia & lymphoma. 14(1-2). 185–187. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact